Abstract Number: 0037 • ACR Convergence 2025
A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…Abstract Number: 0228 • ACR Convergence 2025
Bridging the Gap: Leveraging eConsultation to Improve Access to Quality Gout Care
Background/Purpose: In the context of the rheumatology workforce shortage, eConsultation holds significant potential to address some challenges through supporting primary care providers in managing rheumatologic…Abstract Number: 0231 • ACR Convergence 2025
A Quality Improvement Project to Explore the Implications of the 2020 ACR Gout Guideline Recommendations for HLA-B5801 Testing
Background/Purpose: The presence of the HLA-B5801 allele increases the risk of life-threatening allopurinol hypersensitivity syndrome (AHS). The 2020 ACR gout management guidelines conditionally recommend HLA-B5801…Abstract Number: 1012 • ACR Convergence 2025
Racial and Gender Disparities in Gout Clinical Trials
Background/Purpose: To develop effective novel treatment strategies for Gout disease that cater to patients from diverse backgrounds, it is crucial that all racial groups, without…Abstract Number: 1026 • ACR Convergence 2025
Seasonal Variation in Public Interest in Gout Made More Crystal-Clear: A Longitudinal Infodemiology Study Using Google Trends.
Background/Purpose: Understanding public interest in gout, as reflected by online behavior, can offer valuable insights into its perception and management. Infodemiology, which examines the distribution…Abstract Number: 1032 • ACR Convergence 2025
Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout
Background/Purpose: The role of the gut microbiome has been increasingly implicated in the pathogenesis of gout. For instance, gout patients have shown depletions of bacteria…Abstract Number: 1043 • ACR Convergence 2025
The Care Pathway and Treatment Patterns in Patients with Uncontrolled Gout: A Real-World Survey of Physicians In The United States
Background/Purpose: Uncontrolled gout (UG) is a chronic, progressive, and systemic disease characterized by serum uric acid (sUA) >6 mg/dl and clinical manifestations such as tophi,…Abstract Number: 1076 • ACR Convergence 2025
Racial Differences in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study
Background/Purpose: Although achieving target serum urate (SU) and reducing cardiovascular events are cornerstones of gout management, little is known about contemporary treatment patterns across racial…Abstract Number: 1123 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Background/Purpose: Uncontrolled gout (UG) occurs when serum uric acid (sUA) levels remain persistently elevated despite use of oral urate-lowering therapies and can result in progressively…Abstract Number: 1124 • ACR Convergence 2025
ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations
Background/Purpose: Gout, a condition arising from hyperuricemia, is considered as both a metabolic disorder and an autoinflammatory disease. Genetic factors are estimated to contribute approximately…Abstract Number: 1125 • ACR Convergence 2025
Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout
Background/Purpose: Despite evidence-based recommendations, allopurinol dose escalation to goal serum urate (SU) is frequently suboptimal. The EasyAllo tool was developed to facilitate pre-planned allopurinol dose…Abstract Number: 1128 • ACR Convergence 2025
Association between leptin levels, body mass index and health-related quality of life in patients with gout
Background/Purpose: Gout is s a disease with a high disability rate, resulting in severe social burden and is associated with reduced health-related quality of life…Abstract Number: 1129 • ACR Convergence 2025
Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2I) proved substantial benefits in diabetes mellitus (DM), heart failure (HF) and kidney disease (KD). In pivotal trials, SGLT2Is…Abstract Number: 1130 • ACR Convergence 2025
Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Background/Purpose: Obesity affects >50% of individuals with gout and is the most important modifiable risk factor for gout. Thus, novel anti-obesity medications (AOM, e.g., semaglutide…Abstract Number: 1132 • ACR Convergence 2025
DDX3X Regulates Gout Inflammation via NLRP3 Inflammasome Activation and Macrophage Pyroptosis Crosstalk
Background/Purpose: Pyroptosis is closely linked to acute flare-ups and spontaneous remission of gout. However, the specific mechanisms by which pyroptosis regulates gout inflammation remain unclear.…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »